Ukrainian surgeons operating in the theater of war treated multiple patients with Humacyte’s experimental Human Acellular Vessel (HAV) device and saw highly significant results in the restoration of blood flow in patients, which led to reduced need for amputations. Data also showed low rates of infection in patients. The data will support a planned BLA later this year.
From Pharma to Biotech: Meet Elaine Haynes CEO of Artificial Red Blood Cell Startup KaloCyte
Published on :A collaborative leader, Elaine Haynes leadership style was forged in the crucible of large pharma and sharpened as CEO of Baltimore-based artificial red blood cell startup, KaloCyte.
Baltimore’s KaloCyte Partners on $46M DARPA Program to Develop Synthetic Blood Product
Published on :KaloCyte’s experimental synthetic red blood cell product ErythroMer could provide a solution to the high need for treating trauma in both military and civilian settings. The company was tapped to participate in a federally-funded program to develop a synthetic blood substitute.
A Strategic Relocation to Baltimore Supports One Biomedical Company’s Growth
Published on :KaloCyte cofounders Dr. Allan Doctor and Dr. Dipanjan Pan were slated to relocate to Maryland and launch the Center for Blood Oxygen Transport & Hemostasis at the University of Maryland School of Medicine nearly three years ago.
But instead of being forced to choose between leaving behind their biotech startup and forming CBOTH, they made the best of both worlds right in the heart of Baltimore: The St. Louis-founded startup moved into CBOTH as a University of Maryland BioPark affiliate in July 2019.
The BioPark, located on the University of Maryland, Baltimore’s campus, is home to nearly three dozen life sciences companies. Tenants range from early-stage companies to major global firms like BD, Catalent, Illumina, and Pharmaron. Its prime location in Maryland’s biomedical ecosystem made it an ideal new home for KaloCyte, which is developing a critically-needed red blood cell substitute for use when perishable donor blood is not available or in short supply.
KaloCyte Welcomes Lyophilization Expert to its Baltimore Headquarters
Published on :KaloCyte Welcomes Lyophilization Expert to its Baltimore Headquarters Nivesh Mittal, Ph.D., Product Development Scientist, to propel production of ErythroMer™ March 24, 2020, Baltimore, Md. – KaloCyte, Inc., a preclinical-stage healthcare biotechnology company [….]
Top 10 Podcasts of 2019 from the BioHealth Capital Region
Published on :Top 10 Podcasts of 2019 from the BioHealth Capital Region Check out these Podcasts Featuring Some of the Top Biohealth Industry Leaders and Executives from the Region To say it [….]